News
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year
Pentixapharm Holding AG releases 2024 financial results with EUR 12.8 million net loss and guides for EUR 23.5 million loss in 2025, focusing on R&D and operating expenses -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
First-In-Human Data about the Treatment of Muscle-Invasive Bladder Cancer with Pentixapharm’s Lu177-PentixaTher to be Presented at ASCO-GU 2025
Pentixapharm presents first-in-human data on Lu177-PentixaTher for Muscle-Invasive Bladder Cancer at ASCO-GU 2025, showing potential for bladder preservation and targeted treatment -
-